Checked against the reference
Numerical output is compared against the reference implementation of the published method.
Which paper it comes from, and how we check that the implementation is right.
Provenance
| Design | Original publication |
|---|---|
| BOIN | Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc Ser C. 2015;64(3):507–523. |
| TITE-BOIN | Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-event Bayesian optimal interval design to accelerate phase I trials. Clin Cancer Res. 2018;24(20):4921–4930. |
| BOIN12 | Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding. JCO Precis Oncol. 2020;4:1393–1402. |
| BOP2 | Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med. 2017;36(21):3302–3314. |
| Predictive Probability | Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials. 2008;5(2):93–106. |
| Simon Two-Stage | Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10. |
Regulatory
In December 2021 the FDA designated the local BOIN design fit-for-purpose for identifying the maximum tolerated dose — the first oncology dose-finding design to receive it.
The designation applies to the published method, not to any one software implementation, including ours. Both FDA documents are public: determination letter and statistical review.
Validation
Numerical output is compared against the reference implementation of the published method.
Each design moves through the same review stages before it goes live.
A saved design reopens as exactly what you ran, for you or a colleague.